Literature DB >> 18666267

Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.

Antoni R Blaazer1, Pieter Smid, Chris G Kruse.   

Abstract

Agonist activation of central 5-HT(2A) receptors results in diverse effects, such as hallucinations and changes of consciousness. Recent findings indicate that activation of the 5-HT(2A) receptor also leads to interesting physiological responses, possibly holding therapeutic value. Selective agonists are needed to study the full therapeutic potential of this receptor. 5-HT(2A) ligands with agonist profiles are primarily derived from phenylalkylamines, indolealkylamines, and certain piperazines. Of these, phenylalkylamines, most notably substituted phenylisopropylamines, are considered the most selective agonists for 5-HT(2) receptors. This review summarizes the structure-activity relationships (SAR) of phenylalkylamines as agonist ligands for 5-HT(2A) receptors. Selectivity is a central theme, as is selectivity for the 5-HT(2A) receptor and for its specific signaling pathways. SAR data from receptor affinity studies, functional assays, behavioral drug discrimination as well as human studies are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18666267     DOI: 10.1002/cmdc.200800133

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  8 in total

1.  Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Authors:  Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Robert A Johnson; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2018-09-25       Impact factor: 5.858

2.  Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.

Authors:  Martin Hansen; Karina Phonekeo; James S Paine; Sebastian Leth-Petersen; Mikael Begtrup; Hans Bräuner-Osborne; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2014-01-15       Impact factor: 4.418

3.  Correlating the metabolic stability of psychedelic 5-HT₂A agonists with anecdotal reports of human oral bioavailability.

Authors:  Sebastian Leth-Petersen; Christoffer Bundgaard; Martin Hansen; Martin A Carnerup; Jan Kehler; Jesper Langgaard Kristensen
Journal:  Neurochem Res       Date:  2014-02-12       Impact factor: 3.996

4.  Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.

Authors:  William E Fantegrossi; Bradley W Gray; Jessica M Bailey; Douglas A Smith; Martin Hansen; Jesper L Kristensen
Journal:  Psychopharmacology (Berl)       Date:  2014-09-17       Impact factor: 4.530

5.  DARK Classics in Chemical Neuroscience: NBOMes.

Authors:  Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2019-11-12       Impact factor: 5.780

6.  Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs.

Authors:  Micaela Tirri; Sabrine Bilel; Raffaella Arfè; Giorgia Corli; Beatrice Marchetti; Tatiana Bernardi; Federica Boccuto; Giovanni Serpelloni; Francesco Botrè; Fabio De-Giorgio; Krystyna Golembiowska; Matteo Marti
Journal:  Front Psychiatry       Date:  2022-04-21       Impact factor: 5.435

7.  Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists.

Authors:  Christian B M Poulie; Eline Pottie; Icaro A Simon; Kasper Harpsøe; Laura D'Andrea; Igor V Komarov; David E Gloriam; Anders A Jensen; Christophe P Stove; Jesper L Kristensen
Journal:  J Med Chem       Date:  2022-09-13       Impact factor: 8.039

8.  Metabolic profiling in Caenorhabditis elegans provides an unbiased approach to investigations of dosage dependent lead toxicity.

Authors:  Gita Sudama; John Zhang; Jenefir Isbister; James D Willett
Journal:  Metabolomics       Date:  2012-06-04       Impact factor: 4.290

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.